You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Large-aperture Electrically Tunable Lenses with 40 Microsecond Hysteresis-free response for Remote Focusing

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: 101

    PROJECT SUMMARY This Phase II Lab-to-Marketplace proposal aims to commercialize a new remote focusing technique that can change the focus of a microscope by as much as 500 μm in less than 40 μs, 3 orders of magnitude faster than other discrete focus change techniques. Our initial market is neuroscience imaging, where the ability of researchers to step between focal planes at the millisecond time ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. An add-on microscopy module for fast volumetric imaging

    SBC: MEADOWLARK OPTICS, INC.            Topic: 101

    Project Summary Microscopy with spatial light modulatorsSLMsenables use of optical techniques to simultaneously monitor and manipulate the activity of neuronal ensemblesin vitro and in vivoAs a result of successful worldwide research in this fieldsuppliers of commercial two photon microscopes feel there is extensive product potentialAs suchthree commercial microscope suppliers have licensed patent ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: Neuroene Therapeutics, LLC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Proprietary biologic treatment to heal skin wounds

    SBC: Allander Biotechnologies            Topic: NIDCR

    SUMMARY Chronic skin wounds associated with various diseasese gdiabetesand aberrant healing from acute woundinge ghypertrophic scarringare a major health care burdenThis health burden increases in aging populationsThe cost to treat these conditions exceeds $billion annuallyCurrentlyREGRANEXa cream containing a biologic based on human PDGFPlatelet Derived Growth Factoris the only FDAFood and Drug A ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Smartphone Help for DWI Offenders and Their Families: A B-SMART App

    SBC: KLEIN BUENDEL, INC            Topic: 450

    Driving while intoxicatedDWIremains a substantial and preventable source of morbidity and mortality in the United StatesA variety of sanctions and interventions have been attempted to reduce DWI in the U Sincluding enhanced DWI enforcement effortsstricter drunk driving lawsresponsible alcohol beverage service trainingand alcohol treatmentThe Ignition Interlock DeviceIIDwhich requires a driver to b ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Caminamos: A location-based Smartphone App for Latinas to Connect with Nearby Walking Partners

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Health disparities are high among LatinasThey are more likely to be overweightdiagnosed with diabetesand physically inactive compared to their non Hispanic White counterpartsThusinterventions that target improving health access and ameliorating chronic diseases among Latinas are of high public health importanceAvailable data suggest that community focused interventions produce improvements in phys ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. PINPOINT: Gaming technology to engage adolescent sickle cell patients in precision pain Phase I

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Sickle cell diseaseSCDis the most common inherited blood disorder in the U Sand disproportionately affects African Americans and HispanicsApproximatelyU Schildren are born with SCD annuallySCD results from abnormal hemoglobin and causes red blood cellsRBCsto become misshapedsickle shapedSickled cells can block the flow of blood in small arteries causing tissue and organ damage and other lifethreat ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government